Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Breast Cancer Clinical Trial

Official title:

Randomized, Double-blind, Parallel-controlled Phase III Trial to Evaluate the Efficacy and Safety of TQB3616 Combined With Endocrine Therapy Versus Placebo Combined With Endocrine Therapy in Hormone Receptors (HR)-Positive and Human Epidermal GrowthFactor Receptor-2 (HER2) -Negative Breast Cancer Adjuvant Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05780567
• Other study ID #: TQB3616-III-03
• Status: Recruiting
• Phase: Phase 3
• Start date: March 30, 2023
• Est. completion date: January 2027

Study information

• Verified date: June 2022
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase III, randomized, double-blind, parallel, multi-center trail to evaluate the efficacy and safety of TQB3616 capsule combined with endocrine compared to placebo compared with endocrine in HR-positive and HER2-negative breast cancer adjuvant therapy. Approximately 1946 female subjects will be randomized to either TQB3616 combined with endocrine group or TQB3616-matching placebo combined endocrine group. Randomization will follow a 2:1 ratio, 1297 subjects in experimental group and 649 in the the Placebo Comparator group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1946
• Est. completion date: January 2027
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• The subjects voluntarily joined the study and signed the informed consent, with good compliance.

• Age: 18-75 years old (upon signing the informed consent); Eastern Cooperative Oncology Group Performance Status (PS) score: 0~1;

• Surgical treatment of radical mastectomy;

• Pathological examination confirmed HR positive and HER2 negative invasive breast cancer;

• The major organs are functioning well, meeting the following criteria:

1. Blood biochemical tests should meet the following criteria (no corrective therapy has been used within 7 days prior to screening):

1. Hemoglobin (HB) =90 g/L;

2. Neutrophil absolute value (NEUT) = 1.5×109/L;

3. Platelet count (PLT) = 100 ×109/L;

2. Blood biochemical tests should meet the following criteria (no corrective therapy has been used within 7 days prior to screening):

1. Total bilirubin (TBIL) = 1.5 times the upper limit of normal (ULN);

2. Alanine transferase (ALT) and aspartate transferase (AST) = 1.5×ULN;

3. Serum creatinine (Cr) = 1.5×ULN, or creatinine clearance (Ccr) = 60 ml/min;

3. Blood clotting tests must meet the following criteria (no anticoagulant therapy):

1. Prothrombin time (PT) = 1.5×ULN;

2. Activated partial thromboplastin time (APTT) = 1.5×ULN;

3. International Normalized ratio (INR) = 1.5×ULN.

4. Left ventricular ejection fraction (LVEF) =50%.

Exclusion Criteria:

• Complicated diseases and medical history:

1. Has had other malignant tumors within 5 years or currently has other malignant tumors;

2. Have a variety of factors that affect oral medication (such as inability to swallow);

3. Current history of serious lung disease such as interstitial pneumonia;

4. Severe infections common terminology criteria for adverse events (=CTCAE (common terminology criteria for adverse events) 2 grade) that were active or uncontrolled before the study treatment started (Except hair loss and hemoglobin);

• Known allergy to aromatase inhibitors, tamoxifen, TQB3616/ placebo, or any excipients;

• There was a history of live attenuated vaccine vaccination within 28 days prior to randomization or live attenuated vaccine vaccination was planned during the study period;

• Participated in clinical trials of other antitumor agents within 4 weeks prior to randomization;

• The presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of study participation or interfere with the study results, as well as subjects who are deemed unsuitable for study participation for other reasons by the investigator.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
TQB3616 is a novel Cyclin-dependent kinase (CDK) 4/6 inhibitor and currently being used in the treatment of a variety of malignant solid tumors. Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.
• Placebo capsules, Letrozole, Anastrozole, Tamoxifen
Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.

Locations

Country	Name	City	State
China	Cancer Hospital Chinese Academy of Medical Science	Beijing	Beijing
China	Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University	Guangzhou	Guangdong
China	Suining Central Hospital	Suining	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Invasive Disease-Free Survival (IDFS)	The time from the date of randomization to the first occurrence of the following events, including ipsilateral or contralateral recurrence of invasive breast cancer, regional or distant recurrence of invasive breast cancer, secondary primary malignancy outside the breast, and death from any cause.	Baseline up to 60 months
Secondary	Overall survival (OS)	The time from first administration to death of any cause.	Baseline up to 60 months
Secondary	Disease Relapse Free Survival (DRFS)	The time from the date of randomization to the first occurrence of distant recurrence or death from any cause.	Baseline up to 60 months
Secondary	Incidence of adverse events	Incidence of adverse events assessed according to the common terminology criteria for adverse events (CTCAE).	Baseline up to 60 months
Secondary	Severity of adverse events	Severity of adverse events assessed according to the common terminology criteria for adverse events (CTCAE).	Baseline up to 60 months
Secondary	Incidence of abnormal laboratory test values	Incidence of abnormal laboratory test values assessed according to the common terminology criteria for adverse events (CTCAE).	Baseline up to 60 months
Secondary	Severity of abnormal laboratory test values	Severity of abnormal laboratory test values assessed according to the common terminology criteria for adverse events (CTCAE).	Baseline up to 60 months
Secondary	Incidence of serious adverse events	Incidence of serious adverse events assessed according to the common terminology criteria for adverse events (CTCAE).	Baseline up to 60 months
Secondary	Severity of serious adverse events	Severity of serious adverse events assessed according to the common terminology criteria for adverse events (CTCAE).	Baseline up to 60 months